Discontinuation of Imatinib, Dasatinib or Nilotinib in CML


Discontinuation of Imatinib, Dasatinib or Nilotinib in CML
Slides from presentations at ASH 2011 and transcribed comments from a recent interview with Srdan Verstovsek, MD, PhD (1/25/12)

Mahon FX et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: Update results of the STIM study. Proc ASH 2011;Abstract 603.

Rea D et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia (CML) patients (pts) with stable undetectable bcr-abl transcripts: Results from the French CML group (FILMC). Proc ASH 2011;Abstract 604.

Dr Verstovsek is Associate Professor, Chief of the Section of Myeloproliferative Neoplasms and Director of the Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center in Houston, Texas.